Danaparoid dosing during continuous venovenous hemofiltration - a randomized controlled pilot study investigating two danaparoid dosing schemes with a standard heparin dosing scheme
Phase 2
- Conditions
- acute kindey failureAcute renal failure10038430
- Registration Number
- NL-OMON30497
- Lead Sponsor
- Academisch Medisch Centrum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 18
Inclusion Criteria
Critically ill patients with acute renal failure, needing CRRT.
Exclusion Criteria
-No informed consent
-Use of unfractionated heparin or low molecular weight heparin in therapeutic doses within 24 hours before enrollment
-Extreme coagulation disorders, such as platelet count < 30 x 109/l, PT > 20 sec or APTT > 80 sec.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>*Area under the curve of serial anti-Xa measurements<br /><br>*Circuit survival time<br /><br>*Occurrence and severity of bleeding events</p><br>
- Secondary Outcome Measures
Name Time Method <p>markers of thrombin generation (e.g. thrombin-antithrombin complexes,<br /><br>prothrombin fragment F1+2 and endogenous thrombin potential) </p><br>